Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Status: RECRUITING

Eligibility Criteria

Sex: ALL
Age: Up to 18 years old
Healthy Volunteers: This study is NOT accepting healthy volunteers
Recipient Inclusion Criteria

- Less than 18 years at the time of anticipated transplant
- Participant meets one of the following criteria:

1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or
2. Scheduled to or received solid organ transplant within 7 days before or after enrollment
    - Participant is receiving care at the time of enrollment at one of the study participating institutions.
    - Parent/guardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.

Donor Inclusion Criteria

- Donor for HCT recipient enrolled on the VIPER study.
- Willing and able to provide informed consent.

Exclusion Criteria:

Recipient Exclusion Criteria

None

Donor Exclusion Criteria

- Is not an HCT donor for a participant enrolled on the VIPER study.
- Not available to provide pre-transplant research blood sample.

Conditions & Interventions

Conditions:
Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection

More Information

Description:
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. * To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors .

Contact(s): Lara Danziger-Isakov, MD - Lara.Danziger-Isakov@cchmc.org
Principal Investigator:
Principal Investigator ID:
Phase:
IRB Number:
System ID: NCT05550298